| Symbol | ISCO |
|---|---|
| Name | INTERNATIONAL STEM CELL CORP. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 92131 United States CA 9745 Businesspark Ave |
| Telephone | (760) 940-6383 |
| Fax | — |
| — | |
| Website | http://www.internationalstemcell.com |
| Incorporation | US |
| Incorporated On | 2005 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | BDO USA, LLP;BDO USA, LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001355790 |
| Description | International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCOs core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). Additional info from OTC: |
(99% Neutral) INTERNATIONAL STEM CELL CORPORATION (ISCO) Announces Regulatory Update
Read moreNew Form 8-K - International Stem Cell CORP Filed: 2025-09-16 AccNo: 0001683168-25-007018 Size: 205 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Fina…
Read moreDirector Don Wright 🟢 acquired 562.8K shares (2 derivative) of International Stem Cell CORP (ISCO) at $0.13 Transaction Date: Jun 17, 2025 | Filing ID: 004622
Read moreDirector MAIER PAUL V 🟢 acquired 562.8K shares (2 derivative) of International Stem Cell CORP (ISCO.OB) at $0.13 Transaction Date: Jun 17, 2025 | Filing ID: 004620
Read more(66% Neutral) INTERNATIONAL STEM CELL CORPORATION (ISCO) Reports Net Loss for 2025-03-31
Read moreNew Form ARS - International Stem Cell CORP Filed: 2025-04-24 AccNo: 0000950170-25-058122 Size: 1 MB
Read moreNew Form DEF 14A - International Stem Cell CORP Filed: 2025-04-24 AccNo: 0000950170-25-058111 Size: 5 MB
Read moreOTCQB symbol attribute type Security_Name was changed. Previous value: -. New value: INTL STEM CELL CORP.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: INTL STEM CELL CORP.
Read more